3Inaba T, Yagyu H, Itabashi N, et al. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in lowdensity lipoprotein receptor knockout mice[ J]. Hypertens Res, 2008, 31 (5):999-1005.
4Hrebicek J. PPARs: the role in glucose and lipid homeostasis, insulin resistance and atherosclerosis [ J]. Cesk Fysiol, 2004, 53( 1 ) : 4-16.
5Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons [ J ]. Cardiovasc Diabetol, 2005, 16(4) :14.
6Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet[J]. EurJ Pharmacol, 2006, 536(1-2) :182-191.
7Hiuge A, Tenenbaum A, Maeda N,et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level [ J J. Arterioscler Thromb Vasc Biol, 2007, 27(3):635-641.
8Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy [ J]. Am J Cardiol,2007, 99(6A) :3C-18C.
9Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use[J]. Am J Cardiol, 2008, 101 ( 1 ) :95-97.
10Graham D J, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs[J]. JAMA, 2004,292(21 ) :2585-2590.
